{{medical}}
{{drugbox |
| IUPAC_name = (8S,10S)-8-acetyl-10-[(2S,4S,5S,6S)-<br />4-amino-5-hydroxy-6-methyl-oxan-<br />2-yl]oxy-6,8,11-trihydroxy-1-methoxy-<br />9,10-dihydro-7H-tetracene-5,12-dione
| image =Daunorubicin.svg 
| width = 260px
| CAS_number = 20830-81-3
| ATC_prefix = L01
| ATC_suffix = DB02 
| PubChem = 30323
| DrugBank = APRD00521
| C = 27 | H = 29 | N = 1 | O = 10
| molecular_weight = 527.52 [[克|g]]/[[莫耳|mol]]<br />563.99 [[克|g]]/[[莫耳|mol]] ([[氯化氫|HCl]] 鹽)
| bioavailability = 
| protein_bound = 
| metabolism = [[肝臟|肝臟]]
| elimination_half-life = 26.7 [[小時|小時]]
| excretion = 膽汁及尿液
| pregnancy_category = D ([[美國|U.S.]])
| legal_status = 
| routes_of_administration = 只可用於[[靜脈注射治療|靜脈注射治療]]。若以[[肌肉注射|肌肉注射]]或[[皮下注射|皮下注射]]方式使用，將會會導致嚴重[[壞死|壞死]]。
}}
'''道諾黴素'''（'''Daunorubicin'''或'''daunomycin'''，又名'''柔红霉素'''）是一種屬於[[蒽环类抗生素|蒽环类抗生素]]（anthracycline）類的[[化學治療|化學治療]]藥物，用於治療某些類型的[[癌症|癌症]]（如[[急性骨髓性白血病|急性骨髓性白血病]]（AML）、[[急性淋巴性白血病|急性淋巴性白血病]]（ALL）、[[慢性粒细胞性白血病|慢性粒细胞性白血病]]（CGL）和[[卡波西氏肉瘤|卡波西氏肉瘤]]<ref name=AHFS2016>{{cite web|title=daunorubicin hydrochloride|url=https://www.drugs.com/monograph/daunorubicin-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20170108211655/https://www.drugs.com/monograph/daunorubicin-hydrochloride.html|archivedate=8 January 2017|df=}}</ref>）。最早得自一種學名為''Streptomyces peucetius''的[[鏈黴菌屬|鏈黴菌屬]]生物,名称来自分離出菌株的那塊土地的古老部落名－[[道尼人|道尼人]]（Dauni），以及用來形容其顏色的法語單詞－rubis (紅寶石)<ref name="weiss">{{cite journal |author=Weiss RB |title=The anthracyclines: will we ever find a better doxorubicin? |url=https://archive.org/details/sim_seminars-in-oncology_1992-12_19_6/page/670 |journal=Seminars in Oncology |volume=19 |issue=6 |pages=670–86 |pmid=1462166|date=December 1992}}</ref>。

道諾黴素可減緩或終止癌細胞的成長，通常使用於治療中會搭配一些其他的化療藥物，給藥方式依腫瘤的類型而定。

與阿黴素類似，道諾黴素通過插入和抑制大分子生物合成與DNA相互作用。<ref>{{Cite book|chapter=Protein Synthesis in vitro: Cell-Free Systems Derived from Human Cells|title=Cell-Free Protein Synthesis|url=http://dx.doi.org/10.5772/48563|publisher=InTech|date=2012-10-10|isbn=978-953-51-0803-0|first=Kodai|last=Machida|first2=Mamiko|last2=Masutan|first3=Hiroaki|last3=Imatak}}</ref>這抑制了拓撲異構酶II的進程，該酶使DNA中的超螺旋鬆弛以進行轉錄。道諾黴素在破壞了DNA鏈以進行複制後穩定了拓撲異構酶II複合物，從而防止了DNA雙螺旋被重新密封，從而停止了複製過程。與DNA結合後，道諾黴素插入，其柔紅胺殘基指向小溝。最優先選擇的是兩個相鄰的G / C鹼基對，它們在5'側接一個A / T鹼基對。晶體學表明，道諾黴素誘導的局部退繞角為8°，並且對相鄰鹼基對和第二相鄰鹼基對產生其他構象干擾。<ref>{{Cite journal|title=Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG).|url=http://dx.doi.org/10.1073/pnas.77.12.7204|last=Quigley|first=G. J.|last2=Wang|first2=A. H.|date=1980-12-01|journal=Proceedings of the National Academy of Sciences|issue=12|doi=10.1073/pnas.77.12.7204|volume=77|pages=7204–7208|issn=0027-8424|last3=Ughetto|first3=G.|last4=van der Marel|first4=G.|last5=van Boom|first5=J. H.|last6=Rich|first6=A.}}</ref>它也可以在插入時誘導從染色質中逐出組蛋白。<ref>{{Cite journal|title=Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin|url=http://dx.doi.org/10.1038/ncomms2921|last=Pang|first=Baoxu|last2=Qiao|first2=Xiaohang|date=2013-05-28|journal=Nature Communications|issue=1|doi=10.1038/ncomms2921|volume=4|issn=2041-1723|last3=Janssen|first3=Lennert|last4=Velds|first4=Arno|last5=Groothuis|first5=Tom|last6=Kerkhoven|first6=Ron|last7=Nieuwland|first7=Marja|last8=Ovaa|first8=Huib|last9=Rottenberg|first9=Sven}}</ref> 

==参考文献==
{{reflist}}

== 外部連結 ==
* [https://web.archive.org/web/20060217073906/http://www.cancerbacup.org.uk/Treatments/Chemotherapy/Individualdrugs/Daunorubicin CancerBacup - Individual Drugs]
* [http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682289.html Mediline Plus - Drug Info]

{{化疗药物}}

[[Category:蒽环类|Category:蒽环类]]
[[Category:IARC第2B类致癌物质|Category:IARC第2B类致癌物质]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]